Connect with us

Health

Heart failure is reversed with new gene therapy in animal study: ‘Unprecedented recovery’

Published

on

Heart failure is reversed with new gene therapy in animal study: ‘Unprecedented recovery’

Heart failure has historically been irreversible, but the outcome of a new study suggests that could someday change.

At the University of Utah, scientists used a new gene therapy that was shown to reverse the effects of heart failure in a large animal study.

In the study, pigs with heart failure were found to have low levels of cardiac bridging integrator 1 (cBIN1), a critical heart protein.

BRAIN BLEED SENT JAMIE FOXX INTO A STROKE — WHAT TO KNOW ABOUT THE DANGEROUS CONDITION

The scientists injected a harmless virus into the pigs’ bloodstreams to carry the cBIN1 gene into their heart cells, according to a university press release.

Advertisement

The pigs survived for the six-month duration of the study, while they would have been expected to die from heart failure without the gene therapy.

Senior study co-authors Robin Shaw, MD, PhD (left) and TingTing Hong, MD, PhD (right) are pictured in the lab. (Charlie Ehlert / University of Utah Health.)

In what the researchers called an “unprecedented recovery of cardiac function,” the IV injection appeared to improve heart function by increasing the amount of blood it can pump, which “dramatically improves survival.”

The pigs’ hearts also appeared to be “less dilated and less thinned out” after the therapy, “closer in appearance to that of non-failing hearts.”

‘I’M A HEART SURGEON, HERE’S WHAT YOU SHOULD KNOW ABOUT EGGS, YOUR HEART AND YOUR HEALTH’

Advertisement

While previous attempts to treat heart failure improved function by just 5% to 10%, the gene therapy used in the new study resulted in 30% improvement, according to the researchers.

The study, which was funded by the National Institutes of Health, was published on Tuesday in the journal npj Regenerative Medicine.

Microscope images of failing heart cells (top) and heart cells that received gene therapy (bottom). Cell boundaries, labeled in magenta, are more organized after gene therapy, and the level of cBIN1 protein (green) is higher. (Hong Lab)

“Even though the animals are still facing stress on the heart to induce heart failure, in animals that got the treatment, we saw recovery of heart function and that the heart also stabilizes or shrinks,” said TingTing Hong, MD, PhD, associate professor of pharmacology and toxicology at the University of Utah, in the release.

“We call this reverse remodeling. It’s going back to what the normal heart should look like.”

Advertisement

“A possible new therapy to cure heart failure is on the way,” Hong told Fox News Digital in a statement.

“A possible new therapy to cure heart failure is on the way.”

The researchers were surprised to find that the gene therapy worked so well in large animals at such a low dose, Hong added.

Co-senior author Robin Shaw, MD, PhD, director of the Nora Eccles Harrison Cardiovascular Research and Training Institute at the University of Utah, said the “unprecedented” study ushers in a “new paradigm” for heart failure treatments.

JUST 5 MINUTES OF EXERCISE COULD REDUCE HIGH BLOOD PRESSURE, STUDY FINDS

Advertisement

“Given our treatment efficacy, the complex multi-organ syndrome of heart failure can be reduced to a treatable disease of failing heart muscle,” he told Fox News Digital via email.

“The toxicity of gene therapy increases with dose, so our low dose suggests that our gene therapy approach will be safe for patients.”

While gene therapy has historically been used for rare diseases, the study results suggest that it could also be an effective approach for “acquired disease,” a researcher said. (iStock)

While gene therapy has historically been used for rare diseases, the study results suggest that it could also be an effective approach for “acquired disease,” according to Shaw.

The study did have some limitations, the researchers acknowledged.

Advertisement

“Dose escalation and toxicology studies are still needed for the therapy to move to the next step [toward FDA approval],” Hong noted. 

It is also uncertain whether the gene therapy will work for people who have obtained a natural immunity to the virus that carries the therapy, the researchers said.

The toxicology study is currently underway, and the team plans to start human clinical trials in the fall of 2025, Hong said.

Cardiologists weigh in

Dr. Jasdeep Dalawari, interventional cardiologist and regional chief medical officer at VitalSolution, an Ingenovis Health Company based in Ohio, was not involved in the research but shared his reaction to the findings.

Advertisement

“Gene therapy, precision medicine and personalized health care is the future.”

“Research in the animal phase is always interesting, but the application to human test subjects is necessary in terms of understanding if this approach would have the same effect in humans,” he told Fox News Digital.

While previous attempts to treat heart failure improved function by just 5% to 10%, the gene therapy used in the new study resulted in 30% improvement, according to the researchers. (iStock)

“That said, there are many genetic modifications happening in different diseases, like cystic fibrosis and muscular dystrophy, that are looking at a similar intervention – injecting healthy genes in the hopes of finding cures,” he went on.

“Gene therapy, precision medicine and personalized health care is the future, and I look forward to learning more about this.”

Advertisement

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Dr. Johanna Contreras, advanced heart failure and transplant cardiologist at the Mount Sinai Fuster Heart Hospital in New York City, noted that conventional pharmacological interventions can help to alleviate cardiac stress and “systemic congestion,” but “for the most part, they do not address the pathogenic remodeling of failing heart muscle.”

About 6.7 million adults in the U.S. have heart failure, statistics show. (iStock)

“Gene therapy has emerged as a new modality that could interfere or modify the expression of several proteins, thus it could alter the pathologic remodeling of the heart muscle that exists in heart failure,” Contreras, who also was not involved in the study, told Fox News Digital. 

For more Health articles, visit www.foxnews.com/health

Advertisement

Contreras reiterated that human trials are needed to determine whether this therapy will be effective outside animal models and to identify any “downstream effects.”

“I will look forward to learning more and eventually learning if this could one day be applied to humans with heart failure.”

Advertisement

Health

Melissa Joan Hart, 49, Opens up About Weight Loss in Perimenopause

Published

on

Melissa Joan Hart, 49, Opens up About Weight Loss in Perimenopause


Advertisement




Melissa Joan Hart Opens up About Weight Loss in Perimenopause | Woman’s World




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Alzheimer’s prevention breakthrough found in decades-old seizure drug

Published

on

Alzheimer’s prevention breakthrough found in decades-old seizure drug

NEWYou can now listen to Fox News articles!

A drug that has long been used to treat seizures has shown promise as a potential means of Alzheimer’s prevention, a new study suggests.

The anti-seizure medication, levetiracetam, was first approved by the FDA in November 1999 under the brand name Keppra as a therapy for partial-onset seizures in adults. The approval has since expanded to include children and other types of seizures.

Northwestern University researchers recently found that levetiracetam prevented the formation of toxic amyloid beta peptides, which are small protein fragments in the brain that are commonly seen in Alzheimer’s patients.

The medication was found to prevent the formation of amyloid-beta 42 in both animal models and cultured human neurons, according to the study findings, which were published in Science Translational Medicine.

Advertisement

The effect was also seen in post-mortem human brain tissue obtained from individuals with Down syndrome, who are at high risk for Alzheimer’s disease.

The medication was found to prevent the formation of amyloid-beta 42 in both animal models and cultured human neurons. (iStock)

“While many of the Alzheimer’s drugs currently on the market, such as lecanemab and donanemab, are approved to clear existing amyloid plaques, we’ve identified this mechanism that prevents the production of the amyloid‑beta 42 peptides and amyloid plaques,” said corresponding author Jeffrey Savas, associate professor of behavioral neurology at Northwestern University Feinberg School of Medicine, in a press release. 

“Our new results uncovered new biology while also opening doors for new drug targets.”

HIDDEN BRAIN CONDITION MAY QUADRUPLE DEMENTIA RISK IN OLDER ADULTS, STUDY SUGGESTS

Advertisement

The brain is better able to avoid the pathway that produces toxic amyloid‑beta 42 proteins in younger years, but the aging process gradually weakens that ability, Savas noted. 

“This is not a statement of disease; this is just a part of aging. But in brains developing Alzheimer’s, too many neurons go astray, and that’s when you get amyloid-beta 42 production,” he said. 

The effect was also seen in post-mortem human brain tissue obtained from individuals with Down syndrome, who are at high risk for Alzheimer’s disease. (iStock)

That then leads to tau (“tangles”) — abnormal clumps of protein inside brain neurons — which can kill brain cells, trigger neuroinflammation and lead to dementia.

In order for levetiracetam to function as an Alzheimer’s blocker, high-risk patients would have to start taking it “very, very early,” Savas said — up to 20 years before elevated amyloid-beta 42 levels would be detected.

Advertisement

CLICK HERE FOR MORE HEALTH STORIES

“You couldn’t take this when you already have dementia, because the brain has already undergone a number of irreversible changes and a lot of cell death,” the researcher noted.

The researchers also did a deep dive into previous human clinical data to determine whether Alzheimer’s patients who were taking the anti-seizure drug had slower cognitive decline. They reported that the patients in that category had a “significant delay” in the span from cognitive decline to death compared to those not taking the drug.

“This analysis supports the positive effect of levetiracetam to slow the progression of Alzheimer’s pathology,” the researcher said. (iStock)

“Although the magnitude of change was small (on the scale of a few years), this analysis supports the positive effect of levetiracetam to slow the progression of Alzheimer’s pathology,” Savas said.

Advertisement

Looking ahead, the research team aims to find people who have genetic forms of Alzheimer’s to participate in testing, Savas said.

Limitations and caveats

The study had several limitations, including that it relied on animal models and cultured cells, with no human trials conducted.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Because the study was observational in nature, it can’t prove that the medication caused the prevention of the toxic brain proteins, the researchers acknowledged.

Savas noted that levetiracetam “is not perfect,” cautioning that it breaks down in the body very quickly.

Advertisement

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

The team is currently working to create a “better version” that would last longer in the body and “better target the mechanism that prevents the production of the plaques.”

“You couldn’t take this when you already have dementia, because the brain has already undergone a number of irreversible changes and a lot of cell death.”

The medication’s common documented side effects include drowsiness, weakness, dizziness, irritability, headache, loss of appetite and nasal congestion.

It has also been linked to potential mood and behavior changes, including anxiety, depression, agitation and aggression, according to the prescribing information. In rare cases, it could lead to severe allergic reactions, skin reactions, blood disorders and suicidal ideation.

Advertisement

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Funding for the study was provided by the National Institutes of Health and the Cure Alzheimer’s Fund.

Fox News Digital reached out to the drug manufacturer and the researchers for comment.

Related Article

Alzheimer’s decline could slow dramatically with one simple daily habit, study finds
Continue Reading

Health

Seniors over 80 who eat specific diet may be less likely to reach 100 years old

Published

on

Seniors over 80 who eat specific diet may be less likely to reach 100 years old

NEWYou can now listen to Fox News articles!

Older adults who avoid meat in their golden years may be less likely to reach age 100 than their meat-eating counterparts, new research suggests.

Researchers tracked more than 5,000 adults aged 80 or older who were enrolled in the Chinese Longitudinal Healthy Longevity Survey.

Between 1998 and 2018, data showed that those who did not eat meat were less likely to reach their 100th birthday than those who consumed animal products regularly.

The findings seem to contradict previous studies that have linked vegetarianism and plant-based diets to lower risks of heart disease, stroke, diabetes and obesity.

Advertisement

Most evidence supporting the benefits of plant-based diets comes from studies tracking younger populations, the researchers noted. 

The findings contrast with previous research praising plant-based diets for their positive influence on heart health. (iStock)

The study, published in The American Journal of Clinical Nutrition, points to losses in muscle mass and bone density with age, shifts that can increase the risk of malnutrition and frailty in the “oldest old.”

As people enter their 80s and 90s, the nutritional priority often shifts from preventing long-term chronic diseases to maintaining day-to-day physical function, experts say.

HOW MUCH RED MEAT IS TOO MUCH? EXPERTS WEIGH IN ON FOOD PYRAMID UPDATES

Advertisement

“The headline ‘vegetarians over 80 less likely to reach 100’ sounds surprising, because it contrasts with decades of data linking plant‑forward diets to lower chronic disease risk earlier in life,” Erin Palinski-Wade, a New Jersey-based registered dietitian, told Fox News Digital. 

“However, once you see that this research is limited to adults over the age of 80 who are also underweight — and that this link disappears with the consumption of eggs, dairy and fish — the results are less surprising.”

While diets earlier in life tend to emphasize avoiding long-term disease, older age necessitates nutrients and weight maintenance, experts say. (iStock)

In those over 80, restricting animal proteins may be less likely to promote longevity, according to Palinski-Wade, who was not involved in the study.

Eliminating all animal protein — particularly in a population that may already experience diminished hunger cues — can make it more difficult to meet adequate protein needs, potentially increasing the risk of nutrient deficiencies, the nutritionist said.

Advertisement

ALZHEIMER’S SYMPTOMS COULD BE PREDICTED YEARS IN ADVANCE THROUGH ONE SIMPLE TEST

In addition to a higher tendency to be underweight, older populations also face a greater risk of bone fractures due to lower calcium and protein intake.

Potential limitations

The lower rate of vegetarians reaching 100 was only observed in participants identified as underweight, the researchers noted. No such association was found in people who maintained a healthy weight.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Because being underweight is already linked to greater frailty and mortality risk, the researchers noted that body weight may partly explain the findings, making it difficult to determine whether diet itself played a direct role.

Advertisement

Those incorporating animal-sourced products other than meat were just as likely to live to 100. (iStock)

Additionally, the shortened lifespans were not found in people who continued to eat non-meat animal products, such as fish, dairy and eggs. 

Older adults with these more flexible diets were just as likely to live to 100 as those eating meat, as these foods may provide the nutrients necessary for maintaining muscle and bone health, the researchers noted.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“This is an observational study, so it can only show associations, and does not prove that avoiding meat directly reduces the odds of reaching 100,” Palinski-Wade added.

Advertisement

CLICK HERE FOR MORE HEALTH STORIES

The researchers suggested that including small amounts of animal-sourced foods could help older seniors maintain essential nutrients and avoid the muscle loss often seen in those who stick strictly to plants.

Eliminating all animal protein — particularly in a population that may already experience diminished hunger cues — can make it more difficult to meet adequate protein needs, potentially increasing the risk of nutrient deficiencies. (iStock)

Palinski-Wade offered some guidance for those looking to optimize nutrition later in life.

“For adults in their 80s and beyond, especially anyone losing weight or muscle, the priority should be maintaining a healthy weight and meeting protein and micronutrient needs — even if that means adding or increasing fish, eggs, dairy or well‑planned, fortified plant proteins and supplements.”

Advertisement

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Strict vegan or very low‑protein patterns at that age should be carefully monitored by a dietitian or clinician, with attention to B12, vitamin D, calcium and total protein, according to Palinski-Wade.

“Younger and healthier adults can still confidently use plant‑forward or vegetarian patterns to lower long‑term chronic disease risk,” she added.

Related Article

Scientists reveal the one practice that could prevent dementia as you age
Continue Reading

Trending